Summary
Amgen Inc. (AMGN) filed an 8-K on August 3, 2023, to furnish its second-quarter 2023 earnings press release. The release details the company's financial results for the period ending June 30, 2023, and provides a reconciliation of non-GAAP financial measures. Investors should note that Amgen emphasizes its use of non-GAAP figures to provide a clearer view of its ongoing business performance and liquidity, excluding items like acquisition-related expenses, restructuring costs, and certain investment/divestiture impacts. The company also presented adjusted figures for total revenues and product sales, accounting for foreign exchange impacts, to offer a better understanding of underlying sales trends. Free Cash Flow (FCF) is also highlighted as a key liquidity metric. While these non-GAAP measures are presented to supplement GAAP reporting and aid in comparative analysis, investors are reminded that they are not a substitute for GAAP measures and are not deemed 'filed' under Section 18 of the Exchange Act.
Key Highlights
- 1Amgen announced its second-quarter 2023 financial results via an 8-K filing on August 3, 2023.
- 2The company is furnishing its earnings press release, which includes a detailed reconciliation of non-GAAP financial measures to GAAP.
- 3Key non-GAAP measures discussed include earnings per share, operating income, net income, and operating expenses.
- 4Amgen provides adjusted total revenues and product sales to exclude foreign exchange impacts, offering insight into underlying sales performance.
- 5Free Cash Flow (FCF) is presented as a key liquidity metric.
- 6The press release explains that non-GAAP measures are used internally for performance evaluation and resource allocation.
- 7Information in this 8-K, including the press release, is furnished and not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934.